argenx to host workshop and webcast announcing topline clinical TCL data and preclinical AML data from ARGX-110 program
Workshop and webcast to occur at 12:00 pm ET today
Breda, the Netherlands / Ghent, Belgium – argenx (Euronext Brussels: ARGX), a clinical-stage biopharmaceutical company focused on creating and developing differentiated therapeutic antibodies for the treatment of cancer and severe autoimmune diseases, today announced that it will host a workshop and webcast to discuss new ARGX-110 data, in conjunction with the American Society of Hematology (ASH) Annual Meeting. The data on ARGX-110, a novel anti-CD70 therapeutic antibody, include topline clinical results in T-cell lymphoma (TCL) and preclinical data in acute myelogenous leukemia (AML).
The workshop is being held today at 12:00 pm ET and is titled: CD70 biology targeting TCL and AML. It will showcase promising efficacy of ARGX-110 in TCL patients from phase 1b clinical studies and preclinical data from a collaboration with the Tumor Immunology Lab led by Prof. A. F. Ochsenbein at the University of Bern demonstrating that CD70/CD27 signaling is a novel therapeutic target in acute myeloid leukemia.
ARGX-110 is a SIMPLE Antibody™ targeting CD70, an immune checkpoint target involved in hematological malignancies, several solid tumors and severe autoimmune diseases. ARGX-110 works in three ways: i) blocks growth of tumor cells, ii) kills cancer cells and iii) restores immune surveillance against tumors(Silence K. et al. mAbs 2014; 6 (2):523-532). ARGX-110 is currently being evaluated in hematological and solid tumors.